A study of pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER)

Selvam Bawani1, Wan Ishak Wan Zamaniah1, Cheong Sok Ching1, Teo Soo Hwang2, Muhamad Nor Ibtisam3, Ho Gwo Fuang1, Tan Chih Kiang4, Wong Yoke Fui5, Lim Kue Peng2, Wai Annie Yeeng Wai2, Yahya Abqariah6

1Clinical Oncology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia, 2Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia, 3Department of Radiotherapy & Oncology, General Hospital, Kuala Lumpur, Malaysia, 4Oncology and Nuclear Medicine Department, Thomson Hospital Kota Damansara, Selangor, Malaysia, 5Department of Radiotherapy & Oncology, National Cancer Institute, Putrajaya, Malaysia, 6Department of Social and Preventive Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia

ABSTRACT

Introduction: A treatment combination of pembrolizumab plus platinum and 5-FU (PF) has increased the survival of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although the combination of platinum and gemcitabine (PG) is commonly used for the treatment of R/M HNSCC, its use with pembrolizumab has not been tested. We hypothesize that the combination of pembrolizumab with PG would be comparable to pembrolizumab with PF, as first-line treatment in R/M HNSCC.

Methods: In this open-label, phase 2 single-arm study of pembrolizumab plus PG as first-line treatment in subjects with R/M HNSCC, 63 evaluable subjects with no prior treatment in metastatic setting will be enrolled and given pembrolizumab 200 mg 3 weekly in combination with chemotherapy for up to 6 cycles of platinum (either cisplatin at 35 mg/m2 IV on Day 1 and Day 8 or carboplatin at AUC 5 IV on Day 1 of each 3-week cycle) and gemcitabine at 1000 - 1250 mg/m2 IV on Day 1 and 8 of 3-week cycle. The primary study endpoint will be the Objective Response Rate (ORR) using RECIST 1.1. The study applies a Simon two-stage design, where if at least 7 out of 26 evaluable patients achieved CR/PR in stage I, the study will proceed to stage II.

Current Status: The study was initiated in September 2022 and actively recruiting to achieve the stage I interim analysis. To date, 9 patients have been enrolled.